Host cell proteins in biologics development: Identification, quantitation and risk assessment

@article{Wang2009HostCP,
  title={Host cell proteins in biologics development: Identification, quantitation and risk assessment},
  author={X. Wang and A. Hunter and N. Mozier},
  journal={Biotechnology and Bioengineering},
  year={2009},
  volume={103}
}
  • X. Wang, A. Hunter, N. Mozier
  • Published 2009
  • Biology, Medicine
  • Biotechnology and Bioengineering
  • Host cell proteins (HCPs) are those produced or encoded by the organisms and unrelated to the intended recombinant product. Some are necessary for growth, survival, and normal cellular processing whereas others may be non‐essential, simply carried along as baggage. Like the recombinant product, HCPs may also be modified by the host with a number of post‐translational modifications. Regardless of the utility, or lack thereof, HCPs are undesirable in the final drug substance. Though commonly… CONTINUE READING
    148 Citations
    Host cell proteins in biotechnology‐derived products: A risk assessment framework
    • 28
    The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk‐based management for their control
    • 74
    • PDF
    Identification of a host cell protein impurity in therapeutic protein, P1
    • 5
    Targeted Capture of Chinese Hamster Ovary Host Cell Proteins: Peptide Ligand Discovery
    • 8
    • PDF
    Host cell protein analysis in therapeutic protein bioprocessing – methods and applications
    • 67
    • PDF
    Host cell protein dynamics in recombinant CHO cells
    • 26
    Profiling the effects of process changes on residual host cell proteins in biotherapeutics by mass spectrometry
    • 24

    References

    SHOWING 1-10 OF 45 REFERENCES
    Host cell contaminant protein assay development for recombinant biopharmaceuticals.
    • L. Eaton
    • Chemistry, Medicine
    • Journal of chromatography. A
    • 1995
    • 88
    Measurement of cytokines by bioassays: theory and application.
    • 53
    Downstream processing of monoclonal antibodies--application of platform approaches.
    • 658